Overcoming resistance hurdles

被引：0
|
作者：
Thijssen, Rachel [1 ]
机构：
[1] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia
来源：
BLOOD | 2022年 / 139卷 / 06期
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELL RECEPTOR; CYCLOPHOSPHAMIDE; FLUDARABINE; IBRUTINIB;
D O I：
10.1182/blood.2021014430
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Jebaraj et al1 characterize a novel Bruton tyrosine kinase (BTK) inhibitor, vecabrutinib, that targets mutant BTK C481S and wild-type BTK in preclinical models. This is the first BTK inhibitor that also inhibits interleukin-2-inducible T-cell kinase (ITK) and can still bind to mutant BTK.
引用
收藏
页码：804 / 805
页数：2
相关论文
共 50 条
12345